Inhibrx Biosciences, Inc. INBX
90.61 USD -1.13 (-1.23%)
At closeNov 10, 2026, 4:00 PM EST
89.62 -0.99 -1.09%
After hours · Nov 10, 4:00 PM ET
90.01 Day range 92.90
57.30 52-week range 155.29
- YTD
- +14.70%
- 1 year
- +14.70%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates Inhibrx Biosciences reports Phase 2 HexAgon trial data showing improved response rates for INBRX-106 in head and neck cancer.
benzinga.com Inhibrx To Present Phase 2 INBRX-106 HNSCC Results On Webcast Live On Tuesday, September 8 At 5:00 a.m. PT – Event to be webcast live on Tuesday, September 8 th at 5:00 a.m. PT –SAN DIEGO, Sept. 4, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage
benzinga.com HC Wainwright & Co. Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $245 HC Wainwright & Co. analyst Robert Burns initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $245.
benzinga.com Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027 No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic…
benzinga.com Inhibrx Biosciences Q1 EPS $(2.15) Misses $(1.79) Estimate Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the analyst consensus estimate of $(1.79) by 20.11 percent. This is a 23.21 percent increase over losses…
benzinga.com Inhibrx Cancer Treatment Shows High Response Rates In Head And Neck Cancer Study Inhibrx Biosciences shares rise after Phase 2 INBRX-106 and Keytruda data showed stronger response rates in head and neck cancer.
benzinga.com Inhibrx Reports Interim Phase 2 Data For INBRX-106 in First-Line HNSCC Today, the Company presented preliminary data from 53 patients (25 in the INBRX-106 combination arm and 28 in the control arm) with a data cutoff of May 7, 2026, representing the evaluable population…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com Inhibrx Biosciences To Present Interim Phase 2 HexAgon Study Results For INBRX-106 Plus Keytruda In Head And Neck Cancer On May 11, 2026 Webcast – Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –SAN DIEGO, May 8, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage…
benzinga.com Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com GE Vernova, Boston Scientific, Intuitive Surgical And Other Big Stocks Moving Higher On Wednesday U.S. stocks were higher, with the Dow Jones gaining over 350 points on Wednesday. GE Vernova shares rose 14.1% after beating estimates and raising sales guidance.
benzinga.com Dow Jumps Over 400 Points; Boeing Posts Upbeat Q1 Results US stocks rise, with Dow gaining over 400 points. Dow up 0.87%, NASDAQ up 0.70%, S&P 500 up 0.69%. Utilities sector jumps 1.4%, financials only up 0.1%.- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com 'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters https://www.reuters.com/world/merck-rivals-eye-deal-inhibrx-experimental-cancer-drug-tied-keytruda-sources-say-2026-04-22/- benzinga.com Inhibrx Announces Updated Interim Data From Phase1/2 Ozekibart Combination With Folfiri Evaluation Inhibrx plans to meet with the U.S. Food and Drug Administration (FDA) in the second half of 2026 to discuss plans to initiate a first-line registrational trial in CRC. The Company also plans to…
benzinga.com This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See complete rating changes, including upgrades and downgrades, on Benzinga's analyst ratings page.- benzinga.com Stifel Initiates Coverage On Inhibrx Biosciences with Buy Rating, Announces Price Target of $150 Stifel analyst Dara Azar initiates coverage on Inhibrx Biosciences (NASDAQ:INBX) with a Buy rating and announces Price Target of $150.
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Earnings Scheduled For November 14, 2025 
benzinga.com Stocks Soar To Records After Weak Inflation, Ford Jumps 10%: What's Moving Markets Friday? Wall Street surged to fresh all-time highs Friday as a softer-than-expected inflation reading strengthened market conviction that the Federal Reserve will cut interest rates by 25 basis points at its…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Dow Jumps Over 500 Points; US Consumer Sentiment Declines In October 
benzinga.com Ford, Inhibrx Biosciences, Comfort Systems, Western Union And Other Big Stocks Moving Higher On Friday 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Why Intel Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
- benzinga.com Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Gainers Axcella Health Inc. (NASDAQ: AXLA) shares climbed 196% to $0.3335 after the company announced it was granted a patent for long COVID fatigue treatment.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers
benzinga.com Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.- benzinga.com Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday Gainers Enjoy Technology, Inc. (NASDAQ: ENJY) shares jumped 81.5% to close at $0.31 on Tuesday.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 1214 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 422 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the Thursday's session, 100 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.
- benzinga.com Mid-Morning Market Update: Markets Open Lower; Johnson & Johnson Sales Miss Views Following the market opening Tuesday, the Dow traded down 1.79% to 33,748.82 while the NASDAQ fell 2.56% to 13,499.97. The S&P also fell, dropping, 2.59% to 13,496.29.
- benzinga.com The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week.
- benzinga.com 45 Biggest Movers From Yesterday Gainers
- benzinga.com 30 Stocks Moving In Tuesday's Mid-Day Session Gainers
- benzinga.com 66 Biggest Movers From Yesterday Gainers
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the morning session on Thursday, 67 stocks hit new 52-week lows.
benzinga.com 64 Biggest Movers From Yesterday Gainers- benzinga.com 66 Biggest Movers From Yesterday Gainers Second Sight Medical Products, Inc. (NASDAQ: EYES) shares surged 103.3% to close at $11.77 on Monday on continued momentum from Friday after the company reported FDA approval for its Argus 2s…
- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's session saw 466 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During Thursday's morning session, 316 companies made new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday On Tuesday morning, 113 companies hit new 52-week highs.